Abcam, ab7366, Anti-liver FABP antibody [L2B10]

Size: 50µg
Anti-liver FABP antibody [L2B10] (ab7366) is a mouse monoclonal antibody detecting liver FABP in Western Blot, Flow Cytometry, IHC-P, IHC-Fr, FuncS . Suitable for African green monkey, Cow, Human, Mouse, Rat . - Over 10 publications - Trusted since 2002
Key facts
Host species:Mouse,
Clonality:Monoclonal,
Clone number:L2B10,
Isotype:IgG1,
Carrier free:No,
Reacts with:Human, African green monkey, Cow, Mouse, Rat,
Applications:IHC-Fr, FuncS, WB, Flow Cyt, IHC-PSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Specificity:This monoclonal antibody binds to human liver FABP of both natural and recombinant origin.No reactivity to human intestinal or heart FABP.

Product details:
What is this antibody validated in?
Anti-liver FABP antibody [L2B10] (ab7366) is a mouse monoclonal antibody and is validated for use in Western Blot (WB), Flow Cytometry (Flow Cyt), Immunohistochemistry (IHC-P), Immunohistochemistry (IHC-Fr), Functional Studies in African green monkey, Cow, Human, Mouse, Rat samples.
What is the molecular weight of liver FABP?
Anti-liver FABP [L2B10] (ab7366) specifically detects a band for liver FABP (UniProt: P07148) at a molecular weight of 14kDa.
Trusted by the scientific community
Anti-liver FABP [L2B10] (ab7366) was first used in a scientific publication in 2002 and has been cited over 10 times in peer-reviewed journals.
Reviewed by scientists
Anti-liver FABP [L2B10] (ab7366) has over 5 independent reviews from customers.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein G, Storage buffer-Preservative: 0.1% Sodium azideConstituents: 0.2% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Liver fatty acid binding protein (liver FABP) also known as L-FABP or FABP1 is a small protein with a mass of approximately 14 kilodaltons. It functions mainly in the liver where it binds free fatty acids and other lipophilic substances facilitating their transport within cells. This protein is highly expressed in hepatocytes and also found in the small intestine and kidneys. Its role in binding fatty acids positions it as an important mediator in lipid metabolism making it of interest in a variety of metabolic studies.
Biological function summary
Liver FABP is essential for maintaining lipid homeostasis within cells. It is not part of a larger complex but acts by itself to regulate the intracellular concentration of lipids and protect cells from lipotoxicity. By sequestering fatty acids it prevents these molecules from disrupting cellular membranes or signaling pathways. Liver FABP also participates in the uptake transport and metabolic conversion of fatty acids and their metabolites influencing energy homeostasis and other vital processes.
Pathways
Liver FABP plays a significant role in the fatty acid metabolism and peroxisome proliferator-activated receptor (PPAR) signaling pathways. It acts by modulating the availability of lipid ligands necessary for PPAR activation linking it functionally to these nuclear receptors that control gene expression involved in lipid and glucose metabolism. Liver FABP's association with proteins like FABP2 and FABP4 within these pathways provides insight into its broader metabolic network highlighting its interactions in fatty acid transport and metabolism.
Liver FABP shows a strong connection to metabolic conditions particularly non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes. Its dysregulation is often observed in these disorders which include altered lipid profiles and insulin resistance. Liver FABP is also linked to certain forms of cancer with aberrant expression levels found in some tumor types. The interactions of liver FABP with proteins such as FABP5 in these diseases suggest a potential role in the pathogenesis of metabolic disorders and tumor development making it a candidate for further research and therapeutic targeting.